Scientists identify molecular predictor of prognosis for pancreatic cancer patients

Jul 13, 2010

Pancreatic cancer is one of the most challenging tumors to treat. Identifying patients who have more aggressive disease could better inform treatment decisions and predict survival prognosis. A new finding from scientists at UNC Lineberger Comprehensive Cancer Center may help.

The team analyzed gene profiles of pancreatic tumors from patients with both localized and metastasized disease. They identified a six-gene "signature" associated with metastatic disease. Their study is the first to demonstrate that molecular differences in metastatic pancreatic cancer can be identified at earlier stages and that these differences are predictive of future disease behavior. This finding, if verified in further clinical studies, could help patients and physicians make more informed decisions about treatment and could offer new research opportunities into potential therapeutic targets to treat the disease.

Their findings were reported in the July 2010 issue of the Public Library of Science Medicine.

"In our study we showed our six-gene signature to be superior to current methods used to stage disease and estimate prognosis," says study senior author, Jen Jen Yeh, MD, assistant professor of and pharmacology at the UNC School of Medicine. "If we can better stage patients' disease, we can better determine those who may benefit most from chemotherapy before surgery or from surgery alone. As more therapies become available, this signature may be used to tailor treatment options."

Pancreatic cancer is often not diagnosed until it is advanced because the most common tumor type - called pancreatic ductal adenocarcimona, that comprises over 90 percent of all pancreatic cancer - rarely causes early noticeable symptoms. Survival rates for cancer that has spread are poor, on average only five to eight months. At present, treatment decisions and clinical prognosis are based on tumor size and lymph node status.

Study scientists compared and evaluated 30 tumor samples from patients with early and late-stage disease and identified the six-gene signature associated with late-stage disease. They then tested the prognostic value of this signature on a group of 67 patients with localized pancreatic cancer and confirmed the validity of the signature to identify patients with high-risk, aggressive disease.

At present, the only possibility of cure for is surgery which involves removal of the tumor, usually the head of the pancreas, part of the small intestine, a portion of the stomach, and other nearby tissues, a method called a Whipple procedure.

Says Yeh, "If patients have high risk, aggressive disease, this signature may be helpful for consideration of chemotherapy before surgery or, if patients are at increased risk for complications from the surgery, this information may help them decide whether or not to have the surgery."

Explore further: Discovery could lead to new cancer treatment

add to favorites email to friend print save as pdf

Related Stories

Gene signature may improve colon cancer treatment

Feb 26, 2010

A gene signature, first identified in mouse colon cancer cells, may help identify patients at risk of colon cancer recurrence, according to a recent study by Vanderbilt-Ingram Cancer Center researchers.

Researchers ID gene involved in pancreatic cancer

Mar 02, 2009

Researchers from the University of Michigan Comprehensive Cancer Center have identified a gene that is overexpressed in 90 percent of pancreatic cancers, the most deadly type of cancer.

Recommended for you

Discovery could lead to new cancer treatment

7 hours ago

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications ...

Is the HPV vaccine necessary?

14 hours ago

As the school year starts in full swing many parents wonder if their child should receive the HPV vaccine, which is recommended for girls ages 11-26 and boys 11-21. There are a lot of questions and controversy around this ...

User comments : 0